Foxa1 and Foxa2 Are Required for the Maintenance of Dopaminergic Properties in Ventral Midbrain Neurons at Late Embryonic Stages
Simon Stott(Parkinson's UK), Siew‐Lan Ang(The Francis Crick Institute)
Cited by 86
Related Papers
Trial of Lixisenatide in Early Parkinson’s Disease
|New England Journal of Medicine|2024|302
Cell Aggregation-induced FGF8 Elevation Is Essential for P19 Cell Neural Differentiation
|Molecular Biology of the Cell|2006|48